Foment Bio
Montgomery, US · Founded 2023 · Delaware corporation
Foment Bio develops non-viral, off-the-shelf plasmid gene therapy constructs that trigger in vivo production of regenerative exosomes to restore tissue microvasculature, resolve inflammation, and prevent cell death. The therapy targets age-related and cardiometabolic chronic diseases including heart failure, chronic kidney disease, erectile dysfunction, and wound healing, and has advanced into FDA clinical trials.
Founders & leadership
BC
Ben ChlebinaExecutive
Board
MP
Marc PennBoard director
Reported raises · per SEC filings
Form D private placements$542.5K disclosed across 1 round · 2024
▶$542.5KraisedMar 2025 · 12 investors · PharmaceuticalsRule 506(b)
▶$542.5KraisedMar 2025 · 12 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Marc PennDirector
- Ben ChlebinaExecutive Officer
- Offering amount
- $1M
- Amount sold
- $542.5K
- Minimum investment
- $10K
- First sale
- May 2024
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlap
Companies competing with Foment Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Foment Bio do?
- Foment Bio develops non-viral, off-the-shelf plasmid gene therapy constructs that trigger in vivo production of regenerative exosomes to restore tissue microvasculature, resolve inflammation, and prevent cell death. The therapy targets age-related and cardiometabolic chronic diseases including heart failure, chronic kidney disease, erectile dysfunction, and wound healing, and has advanced into FDA clinical trials.
- How much funding has Foment Bio raised?
- Foment Bio has disclosed $542.5K raised across 1 round.
- Where is Foment Bio headquartered?
- Foment Bio is headquartered in Montgomery, US.